Epidural spinal canal angiolipoma

Summary

Epidural spinal canal angiolipoma (MONDO:0002712) is a disease. A subtype of epidural spinal canal neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	epidural spinal canal angiolipoma
Mondo ID	MONDO:0002712
DOID	DOID:3617
NCIT	C5424
UMLS	C1333416
MedGen	232461
Anatomy (UBERON)	UBERON:0003691
Is cancer (heuristic)	no

Also known as: angiolipoma of epidural space · angiolipoma of epidural spinal canal · angiolipoma of the epidural spinal canal · angiolipoma of the extradural spinal canal · epidural space angiolipoma · extradural spinal canal angiolipoma

Disease family

This is a subtype of epidural spinal canal neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › skeletal system disorder › vertebral column disorder › epidural spinal canal neoplasm › epidural spinal canal angiolipoma

Related subtypes (1): intradural extramedullary spinal canal neoplasm

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.